Serbin Creative, Inc.

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbincreative.com LA / NY / UK

Vedolizumab® 

Prev Next
Previous

Surgery - Removing Nodal Packet

illustration of Monoclonal antibody drug Vedolizumab®. An anti-integrin therapy with a selective mechanism of action, for use in primary types of inflammatory bowel disease — ulcerative colitis and Crohn's disease. 

Part of a series;  Drug's mechanism of action graphics at cellular level for pharmaceutical project.

Keywords: molecular biology, cellular biology, histology, pharmacology, virology, disease management
Next illustration of Part of a series; E-learning and booth graphics for therapeutic monoclonal antibody Daclizumab (Zenapax®) — Showing blockage of IL-2 receptor target.

Drug's mechanism of action graphics at cellular level for pharmaceutical project.

Keywords: molecular biology, cellular biology, histology, pharmacology, virology, disease management; multiple sclerosis

Daclizumab— Blockage of dendritic cell receptor

Monoclonal antibody drug Vedolizumab®. An anti-integrin therapy with a selective mechanism of action, for use in primary types of inflammatory bowel disease — ulcerative colitis and Crohn's disease. Part of a series; Drug's mechanism of action graphics at cellular level for pharmaceutical project. Keywords: molecular biology, cellular biology, histology, pharmacology, virology, disease management

Keywords: Line with Color, Action, Corporate, Education, Health, Information Graphics, Medical, Product, Science, Scientific

© Mica Duran